Managing Suicidal Thoughts, Behaviors, and Risk in Treatment-Resistant Depression
A range of therapeutic targets are likely to be relevant for reducing risk of suicide in TRD. Here's what you need to know.
Source: psychiatrictimes.com
📰 Ther Adv News
Ther Adv News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ther Adv. Real-time updates on events, politics, business and more.
Zuranolone Introduces Convenience to Postpartum Depression Care
The FDA approved zuranolone for postpartum depression in August, and the drug recently hit the market for patients this month. Experts are celebrating its delivery of care and rapid response rate.
Source: hcplive.com
Continued Cannabis Confusion
Should cannabis be regulated in the United States in a manner similar to alcohol and tobacco?
United States New Hampshire Exeter Hospital Sergey Adobestock Bhattacharyyas Cannabidiol National Academies
Source: psychiatrictimes.com
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Source: investegate.co.uk
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1...
Source: prnewswire.com
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1...
Source: prnewswire.com
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable saf...
Source: businessinsider.com
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Source: investegate.co.uk
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...
Source: prnewswire.com
Novartis Kymriah® demonstrates strong responses in
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 ...
Source: globenewswire.com